Urology wRVU Compensation in 2026: Benchmarks, ASC Income, In-Office Procedures, and What to Ask Before You Sign

Urology compensation has a structure that rewards practices with diverse revenue streams. The base wRVU compensation is meaningful but not exceptional. The real income leverage in urology comes from ambulatory surgery center ownership, in-office procedure revenue (cystoscopy, prostate biopsy, vasectomy, IPP placement), and the increasing presence of in-office lithotripsy and laser systems. Contracts that hide or minimize these revenue streams quietly cost urologists significant money.

If you are a urologist evaluating a contract — finishing residency, joining a private group, or considering a hospital-employed model — here is what the 2026 market actually looks like and where the financial issues hide.

What the 2026 urology benchmarks actually are

Based on MGMA 2025 data, the median urologist produces approximately 6,800 wRVUs annually at $62 per wRVU. Total compensation at the median runs $475,000-$525,000 in clinical-only practices, with significantly more income available in practices with ASC ownership and high in-office procedural volume.

The 75th percentile urologist produces around 8,400 wRVUs annually. The 90th percentile is 10,200 — typically reflecting either a high-volume general urology practice or an oncology-focused urology practice with significant cystectomy and radical prostatectomy volume.

Urology is meaningfully affected by the 2026 CMS efficiency adjustment. TURP, TURBT, prostate biopsy, cystoscopy, and most other urologic procedures carry slightly reduced wRVU values in 2026 versus 2025.

The three urology contract traps

ASC ownership terms with vesting periods longer than typical contract length. Many urology practices offer ambulatory surgery center ownership opportunities. These can be substantial — a meaningful stake in a high-volume urology ASC can generate $150,000-$400,000 annually in distributions. But vesting terms often extend 5-7 years, and many contracts include language allowing the ASC to repurchase your stake at book value if you leave before vesting completes.

Book value of an ASC stake is typically a small fraction of fair market value. If you sign a 3-year contract with a 5-year ASC vesting schedule, you have created an automatic financial penalty for changing jobs that may not be obvious at the time of signing.

In-office procedure revenue captured by the practice rather than the urologist. Urology practices increasingly invest in in-office equipment — laser lithotripsy systems, in-office IPP placement capability, in-office cystoscopy suites, and shock wave therapy systems. These investments generate technical fee revenue that often does not flow to the urologist who performs the procedures.

Fair contract language addresses this explicitly: either the technical fee revenue flows to a bonus pool that includes the performing urologist, or the urologist's compensation is structured at a higher per-wRVU rate that effectively captures a share of the practice revenue. Vague language that leaves the technical fees with 'the practice' without further definition is a financial trap.

Call coverage with no defined frequency or stipend. Urology call is generally less intense than other surgical specialties but still requires response — emergent stone management, prostatic obstruction, scrotal pathology. Many urology contracts include language requiring call coverage on a rotating basis with no defined frequency cap.

Fair contract language defines the maximum call frequency (commonly 5-8 nights per month for a urology group) and provides separate per-call compensation that scales with case volume during the call window.

What fair urology contract language looks like

On the wRVU structure: a threshold at or below the 50th percentile (around 6,800 wRVUs) with a rate at or above $62/wRVU, explicitly benchmarked against 2026 (not 2025) MGMA data.

On ASC ownership: explicit vesting schedule, buyout methodology that reflects fair market value (not book value), and disclosed historical distributions over the past 3-5 years.

On in-office procedure revenue: transparent language about technical fee allocation, with revenue share back to the performing urologist either through a bonus pool or through an elevated per-wRVU rate.

On call: a defined frequency cap and separate per-call compensation that scales with case volume.

What to ask before you sign

Four specific questions worth getting answered in writing before you commit to a urology contract:

1. If this contract includes ASC ownership opportunity, what is the vesting schedule, the buyout methodology if I leave before vesting, and the historical annual distribution amount?
2. What happens with in-office procedure technical fees (lithotripsy, in-office IPP, in-office cystoscopy), and is there revenue share back to the performing urologist?
3. What is the maximum frequency of call I will be scheduled for, and is there separate per-call compensation?
4. Was the wRVU threshold in this contract benchmarked against 2025 or 2026 MGMA values, given the CMS efficiency adjustment to procedural codes?

These are reasonable questions. Vague answers on ASC vesting, technical fee allocation, or call structure tell you exactly how the math will work in practice.

Want to know how your specific urology contract compares to these benchmarks? FairRVU runs the full analysis in 60 seconds — wRVU threshold percentile, ASC vesting evaluation, in-office procedure revenue analysis, and 2026 CMS adjustment impact. Your contract is permanently deleted after processing.